Prophylactic total gastrectomy for individuals with germline CDH1 mutation

被引:57
作者
Pandalai, Prakash K. [1 ]
Lauwers, Greg Y. [2 ]
Chung, Daniel C. [3 ]
Patel, Devanshi [4 ]
Yoon, Sam S. [1 ,5 ]
机构
[1] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Ctr Canc Risk Anal, Boston, MA 02114 USA
[5] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA
关键词
DIFFUSE GASTRIC-CANCER; E-CADHERIN GENE; LYMPH-NODE DISSECTION; RING-CELL-CARCINOMA; BREAST-CANCER; RECONSTRUCTION; SURVEILLANCE; POPULATION; MANAGEMENT; FAMILIES;
D O I
10.1016/j.surg.2010.07.005
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Germ line mutation of the CDH1 gene, which encodes for the E-cadherin adhesion protein, is rare but confers an estimated lifetime risk of hereditary diffuse gastric cancer of 87%. Fewer than 100 prophylactic total gastrectomies have been reported for this condition. Methods. Patients with germline CDH1 mutation who underwent multidisciplinary counseling followed by prophylactic total gastrectomy were reviewed. Results. Ten patients (6 male, 4 female) with a median age of 42 years (range, 26-51) underwent prophylactic total gastrectomy between 2006 and 2009. Of the 6 families represented, there were 4 missense, 1 frameshift, and 1 splice site mutation. Median time from genetic testing to surgery was 3 months (range, 1-7). All patients had an upper endoscopy before surgery, identifying only 1 patient with a focus of diffuse gastric cancer After prophylactic total gastrectomy, extensive pathologic analysis demonstrated that 9 patients had up to 77 foci of noninvasive cancel; anal, 2 of these patients had 4-12 foci of T1 invasive cancer Median operative time was 213 minutes; there were no. anastomotic leaks, and the length of stay was 7-8 days. One patient had a complication within 30 days (pulmonary embolism), and 3 patients had late complications (2 small bowel obstructions and 1 anastomotic stricture). Median weight loss at 6 months was 19%. Conclusion. The majority of patients with germline CDH1 mutation have foci of noninvasive or invasive gastric cancer by middle age. Serial upper endoscopies provide inadequate screening. Prophylactic total gastrectomy is the procedure of choice for definitive treatment. (Surgery 2011;149:347-55.)
引用
收藏
页码:347 / 355
页数:9
相关论文
共 43 条
[11]   Laparoscopic and open gastric resections for malignant lesions - A prospective, comparative study [J].
Dulucq, JL ;
Wintringer, P ;
Stabilini, C ;
Solinas, L ;
Perissat, J ;
Mahajna, A .
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2005, 19 (07) :933-938
[12]   Completely laparoscopic total and partial gastrectomy for benign and malignant diseases: A single institute's prospective analysis [J].
Dulucq, JL ;
Wintringer, P ;
Perissat, J ;
Mahajna, A .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2005, 200 (02) :191-197
[13]  
Ekström AM, 2000, INT J CANCER, V87, P133, DOI 10.1002/1097-0215(20000701)87:1<133::AID-IJC20>3.0.CO
[14]  
2-E
[15]   Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy - A randomized trial [J].
Fein, Martin ;
Fuchs, Karl-Hermann ;
Thalheimer, Andreas ;
Freys, Stephan M. ;
Heimbucher, Johannes ;
Thiede, Arnulf .
ANNALS OF SURGERY, 2008, 247 (05) :759-765
[16]   Clinical implications of E-cadherin associated hereditary diffuse gastric cancer [J].
Fitzgerald, RC ;
Caldas, C .
GUT, 2004, 53 (06) :775-778
[17]  
Gayther SA, 1998, CANCER RES, V58, P4086
[18]  
Grant J P, 1996, Nutr Clin Pract, V11, P43, DOI 10.1177/011542659601100243
[19]   E-cadherin germline mutations in familial gastric cancer [J].
Guilford, P ;
Hopkins, J ;
Harraway, J ;
McLeod, M ;
McLeod, N ;
Harawira, P ;
Taite, H ;
Scoular, R ;
Miller, A ;
Reeve, AE .
NATURE, 1998, 392 (6674) :402-405
[20]   Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial [J].
Hartgrink, HH ;
van de Velde, CJH ;
Putter, H ;
Bonenkamp, JJ ;
Kranenbarg, EK ;
Songun, I ;
Welvaart, K ;
van Krieken, JHJM ;
Meijer, S ;
Plukker, JTM ;
van Elk, PJ ;
Obertop, H ;
Gouma, DJ ;
van Lanschot, JJB ;
Taat, CW ;
de Graaf, PW ;
von Meyenfeldt, MF ;
Tilanus, H ;
Sasako, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2069-2077